Rapid immunization against H5N1: A randomized trial evaluating homologous and cross-reactive immune responses to AS03A-adjuvanted vaccination in adults

Journal of Infectious Diseases

Volumn 204, Issue 4, 2011, Pages 574-581

  Lasko, Benjamin ^a   Reich, Dennis ^b   Madan, Anuradha ^c   Roman, Francxois ^d   Li, Ping ^c   Vaughn, David ^c  

^a Manna Research   (Canada)

^b Medicor Research   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENETIC DRIFT; GEOGRAPHIC ORIGIN; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STRAIN DIFFERENCE; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 79960880600     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir328     Document Type: Article

References (18)

1. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 6 May 2010. Available at: http://www.who.int/csr/disease/avian-influenza/country/cases-table-2010-05-06/ en/index.html. Accessed 22 July 2010.
2. Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza-Mataftsi E. Influenza A(H5N1): an overview of the current situation. Eurosurveillance 2009; 14:1-4.
3. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies formitigating an influenza pandemic. Nature 2006; 442:448-52.
4. Germann TC, Kadau K, Longini IM, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A 2006; 103:5935-40.
5. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-8.
6. Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458-60. (Pubitemid 44093332)
7. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1345-51.
8. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665.
9. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine. Lancet 2007; 370:580-9. (Pubitemid 47247854)
10. A-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90.
11. Rümke HC, Bayasb JM, de Juanesc JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88.
12. World Health Organization. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. March 2007. Available at: http://www.who.int/csr/disease/ avian-influenza/guidelines/summaryH520070403.pdf. Accessed 22 July 2010.
13. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika 1934; 26:404-13.
14. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods (method 5). Statist Med 1998; 17:873-90. (Pubitemid 28185166)
15. Longini IM Jr, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005; 309:1083-7. (Pubitemid 41134467)
16. Neuzil KM. Pandemic influenza vaccine policy: considering the early evidence. New Engl J Med 2009; 361:e59.
17. A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial. The Journal of Infectious Diseases 2011; 203:1054-62.
18. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383-91.